KLK3, kallikrein related peptidase 3, 354

N. diseases: 358; N. variants: 19
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.070 AlteredExpression disease BEFREE Additionally, overexpression of AR suppressed ENZ-induced autophagy-related genes (LC3-II/I, ATG5, and p-AMPKα) in T24 cells, and CQ exerted synergistic effects with ENZ to suppressed AR-responsive genes expression (KLK2 and KLK3) in bladder cancer. 31574376 2019
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.070 GeneticVariation disease BEFREE All patients had received extensive evaluation to rule out prostate cancer and BC at the bladder neck and prostatic urethra (PU), including prostate specific antigen blood analysis, transrectal ultrasound and/or prostate biopsies, PU biopsies and/or PU frozen section analysis. 29929902 2018
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.070 Biomarker disease BEFREE However, reliable positivity for PAX8, patchy GATA3, and negative staining for PSA, NKX3.1, and prostein aid in distinguishing from prostate cancer and tubular variants of bladder cancer. 29241741 2018
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.070 Biomarker disease BEFREE This protocol describes the generation of bladder tumors in female C57BL/6J mice using the murine bladder cancer cell line MB49, which has been modified to secrete human Prostate Specific Antigen (PSA), and the procedure for the confirmation of tumor implantation. 28117816 2017
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.070 Biomarker disease BEFREE Unlike miR-615-3p, the urinary- exosomal miR-2909 recruitment was not only observed conspicuously in subjects having prostate cancer in comparison to bladder cancer but also the extent of urinary exosomal miR-2909 recruitment showed characteristic variation as a function of prostate cancer aggressiveness as compared to that of either urinary- exosomal miR-615-3p level or existing widely recognised serum prostate specifics antigen (PSA) biomarker of this cancer. 28764970 2017
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.070 Biomarker disease BEFREE Follow-up analyses after RC should include PSA measurements also in low-risk PCa as a considerable number of patients develop biochemical recurrence and metastases from PCa partly ending up with death related to PCa in patients suffering from BC. 27956007 2017
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder
0.070 Biomarker disease BEFREE The expression of CAT activity was clearly observed when PSARPSAP-CAT plasmid was transfected into PSA-positive LNCaP cells, whereas no CAT activity was detected in PSA-negative DU145 cells or bladder carcinoma T24 cells. 11598449 2001